Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172917 | 1.00 | GCK (0.54) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL2651442 | 0.87 | GCK (0.48) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL2658257 | 0.87 | GCK (0.48) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL2651446 | 0.87 | GCK (0.48) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL2658259 | 0.87 | GCK (0.48) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL2663853 | 0.87 | GCK (0.47) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL2658164 | 0.87 | GCK (0.47) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL6174666 | 0.87 | GCK (0.47) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL2658171 | 0.87 | GCK (0.47) | GCKMEN1KMT2ALMNAUSP2 | |
| SCHEMBL6173642 | 0.85 | GCK (0.46) | GCKMEN1KMT2ALMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1209362-C | Tetrazolyl-phenyl acetamide glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-07-06 | — | — | CN | claimed |
| EP-1311504-B1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | claimed |
| US-6369232-B1 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-04-09 | — | — | US | claimed |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | claimed |
| CN-1209362-C | Tetrazolyl-phenyl acetamide glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-07-06 | — | — | CN | disclosed |
| EP-1311504-B1 | TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| CN-1466584-A | Tetrazolyl-phenyl acetamide glucokinase activators | - | 2004-01-07 | — | — | CN | disclosed |
| US-6441180-B1 | TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES | HOFFMANN-LA ROCHE INC. | 2002-08-27 | — | — | US | disclosed |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-05-30 | — | — | US | disclosed |
| US-6388088-B1 | ANTIDIABETIC AGENTS | HOFFMAN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| US-6369232-B1 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-04-09 | — | — | US | disclosed |
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | SIDDURI ACHYUTHARAO (US) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035267-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | GCK 2/4885MEN1 4415/4885KMT2A 1549/4885 |
| US-20020035266-A1 | Tetrazolyl-phenyl acetamide glucokinase activators | GCKR, GCK, PCK1 | GCK 2/4885MEN1 4415/4885KMT2A 1549/4885 |
| US-20020065275-A1 | Tetrazolyl-phenyl actamide glucokinase activators | GCKR, GCK, PFKL | GCK 2/4885MEN1 3886/4885KMT2A 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.